Considerations for Home-Based Treatment of Fabry Disease in Poland during the COVID-19 Pandemic and Beyond

Is home-based therapy in Fabry disease the answer to compelling patients’ needs during the COVID-19 pandemic? Survey results from the Polish FD Collaborative Group

(2021) Mariusz Kusztal et al.   Advances in Clinical and Experimental Medicine

Home infusion therapy with agalsidase alfa for patients with Fabry disease in Germany and Austria

(2020) Anja Lachmann et al.   MOLECULAR GENETICS AND METABOLISM

Supporting the Health Care Workforce During the COVID-19 Global Epidemic

(2020) James G. Adams et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impact of COVID-19 related healthcare crisis on treatments for patients with lysosomal storage disorders, the first Italian experience

(2020) Annalisa Sechi et al.   MOLECULAR GENETICS AND METABOLISM

Virtually Perfect? Telemedicine for Covid-19

(2020) Judd E. Hollander et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telemedicine in the Time of COVID and Beyond

(2020) Steve North   JOURNAL OF ADOLESCENT HEALTH

Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued

(2020) Juan Politei   MOLECULAR GENETICS AND METABOLISM

Impact of COVID-19 pandemic on patients with Fabry disease: An Italian experience

(2020) Eleonora Riccio et al.   MOLECULAR GENETICS AND METABOLISM

Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion

(2018) Malte Lenders et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study

(2018) Maarten Arends et al.   JOURNAL OF MEDICAL GENETICS

Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease

(2018) Malte Lenders et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Use of telehealth in the delivery of comprehensive care for patients with haemophilia and other inherited bleeding disorders

(2017) R. Kulkarni   HAEMOPHILIA

Time delays in the diagnosis and treatment of Fabry disease

(2017) Ricardo Reisin et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Telehealth Interventions to Support Self-Management of Long-Term Conditions: A Systematic Metareview of Diabetes, Heart Failure, Asthma, Chronic Obstructive Pulmonary Disease, and Cancer

(2017) Peter Hanlon et al.   JOURNAL OF MEDICAL INTERNET RESEARCH

Towards a shared service centre for telemedicine: Telemedicine in Denmark, and a possible way forward

(2016) Simon Bo Larsen et al.   Health Informatics Journal

Infusionsbehandlung in häuslicher Umgebung – ein praktikabler Ansatz für chronisch Kranke?

(2013) M. Beck et al.   DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT

A revised home treatment algorithm for Fabry disease: Influence of antibody formation

(2012) B.E. Smid et al.   MOLECULAR GENETICS AND METABOLISM

Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome

(2012) Saskia M. Rombach et al.   PLoS One

Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion

(2010) Julian F. Guest et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Effects of enzyme replacement therapy in Fabry disease—A comprehensive review of the medical literature

(2010) Olivier Lidove et al.   GENETICS IN MEDICINE

A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease

(2009) Catharina Whybra et al.   GENETICS IN MEDICINE

Effects of enzyme replacement therapy on the cardiomyopathy of Anderson Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

(2007) D A Hughes et al.   HEART

Safety and Efficacy of Enzyme Replacement Therapy with Agalsidase Beta: An International, Open-label Study in Pediatric Patients with Fabry Disease

(2007) J. Edmond Wraith et al.   JOURNAL OF PEDIATRICS